Karyopharm Shares Climb Following European Commission's Marketing Authorisation For Multiple Myeloma Candidate
The European Commission (EC) has granted Marketing Authorisation for Karyopharm Therapeutics’ (NASDAQ: KPTI) lead candidate NEXPOVIO (selinexor) in combination with once-weekly bortezomib (Velcade) and low-dose dexamethasone (SVd) for the treatment of adults with multiple myeloma who have received at
